RARA CRAFT DATABASE for FDA Medical Devices
510(k)K254189

FDA DEVICE FACTS

Synapse 3D Base Tools (V7.2)

Fujifilm Corporation

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

AI/ML
DECISION DATEApril 30, 2026PRODUCT CODEQIHCLINICAL AREARadiology

Indications for use

Synapse 3D Base Tools is medical imaging software that is intended to provide trained medical professionals with tools to aid them in reading, interpreting, reporting, and treatment planning. Synapse 3D Base Tools accepts DICOM compliant medical images acquired from a variety of imaging devices including, CT, MR, CR, US, NM, PT and XA. This product is not intended for use with or for the primary diagnostic interpretation of Mammography images. Synapse 3D Base Tools provides several levels of tools to the user:

- Basic imaging tools for general images, including 2D viewing, volume rendering and 3D volume viewing, orthogonal / oblique / curved Multi-Planar Reconstructions (MPR), Maximum Intensity Projection (MIP), Average Intensity Projection (RaySum) and Minimum Intensity Projection (MinIP), 4D volume viewing, image fusion, image subtraction, surface rendering, sector and rectangular shape MPR image viewing, MPR for dental images, creating and displaying multiple MPR images along an object, time-density distribution, basic image processing, noise reduction, CINE, measurements, annotations, reporting, printing, storing, distribution, and general image management and administration tools.

- Regional segmentation tools for anatomical structures within image data, including path definition through vascular and other tubular structures and boundary detection.

- Modality-specific image viewing tools, including fusion and ADC image viewing for MR studies.

- General imaging tools for CT images, including virtual endoscopic viewing, dual energy image viewing, and segmentation of ROI based on user-specified locations.

- General imaging tools for MR images, including diffusion-weighted MRI viewing.

- Cardiac analysis for MR heart images, including delayed enhancement image viewing, functional characteristics viewing, and calcium scoring.

- Blood flow analysis for multi-phase and velocity-encoded MR images, including blood flow velocity and direction analysis.

- Lung analysis for non-contrast and contrast-enhanced CT images, including boundary detection and volume calculation for pulmonary nodules based on user-specified locations, segmentation of bronchial tubes, approximation of air supply regions by user-defined bronchial tubes, identification and processing of low absorption regions, analysis of bronchial pathways to reach lung nodules using CT volume data, and simulation of bronchoscope insertion along the path.

- Liver analysis for contrast-enhanced CT images, including liver and peripheral organ segmentation, tumor segmentation based on user-specified locations, segmentation of intrahepatic and peripheral vessels, and approximation of vascular territories.

- Tensor analysis for neck and head MR images, including diffusion and FA color maps, white matter tractography, dynamic MR review, and vessel and body visualization with registration of MR, CT, XA, PET, and NM.

- Perfusion analysis for dynamically scanned cerebral CT arteriography, including parameters such as blood volume (BV), blood flow (BF), mean transit time (MTT), and time to peak (TTP).

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 22, 2026